Search research articles
Contact Us
Filters
Showing results (71-80 of 130) with videos related to
Page
of 13
Sort By:
Cell Reports. Medicine
|
April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
Joseph J Sacco, Peter Kirk, Emma Leach, et al.
Cancer Research Communications
|
March 2, 2023
Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
Derek Wong, Ping Luo, Nadia Znassi, et al.
Cell Reports
|
August 28, 2025
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab
Shirin Soleimani, Xuan Li, Ben X Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
Cancer
|
February 16, 2019
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
Yada Kanjanapan, Daphne Day, Lisa Wang, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
American Journal of Clinical Dermatology
|
October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Laurent Mortier, Lisa Villabona, Ben Lawrence, et al.
Translational Oncology
|
August 24, 2025
Elucidating divergent biology in uterine carcinosarcoma
Vikas Garg, Stephenie D Prokopec, Simone C Stone, et al.
Journal for Immunotherapy of Cancer
|
March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Aung Naing, Justin F Gainor, Hans Gelderblom, et al.
Blood
|
July 19, 2003
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells
Britta Maecker, David H Sherr, Robert H Vonderheide, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 130) with videos related to
Sort By:
Page
of 13
Cell Reports. Medicine
|
April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
Joseph J Sacco, Peter Kirk, Emma Leach, et al.
Cancer Research Communications
|
March 2, 2023
Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
Derek Wong, Ping Luo, Nadia Znassi, et al.
Cell Reports
|
August 28, 2025
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab
Shirin Soleimani, Xuan Li, Ben X Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
Cancer
|
February 16, 2019
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
Yada Kanjanapan, Daphne Day, Lisa Wang, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
American Journal of Clinical Dermatology
|
October 8, 2024
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Laurent Mortier, Lisa Villabona, Ben Lawrence, et al.
Translational Oncology
|
August 24, 2025
Elucidating divergent biology in uterine carcinosarcoma
Vikas Garg, Stephenie D Prokopec, Simone C Stone, et al.
Journal for Immunotherapy of Cancer
|
March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
Aung Naing, Justin F Gainor, Hans Gelderblom, et al.
Blood
|
July 19, 2003
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells
Britta Maecker, David H Sherr, Robert H Vonderheide, et al.
Page
of 13